22nd February 2010: Recipharm AB is pleased to announce that following the successful acquisition of Cobra Biomanufacturing plc, it has now combined it with the existing Biologics activities located in Sweden. The integrated business will be known as RecipharmCobra Biologics and will operate as Recipharm’s specialist biologics division.
The combination of both companies capabilities creates a comprehensive biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop concept for their biologics outsourcing needs.
Simon Saxby, former CEO of Cobra Biomanufacturing, will head up RecipharmCobra Biologics in the newly formed position of Vice President, Biologics.
With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford, UK and Södertälje, Sweden.
RecipharmCobra Biologics holds significant IP and licences in expression technologies, including ORT-VAC and UCOE, platform expression technologies that deliver cost effective production of customer materials.
Thomas Eldered, CEO of Recipharm AB commented: “Integrating the experience of Cobra Biomanufacturing’s staff, expertise and established services with our own previous offering has, we believe, created a much stronger force in the industry’s biologics outsourcing sector. Indeed, in addition to antibodies and rProteins, our integrated company competitively offers both process development and cGMP manufacturing services for viruses, DNA and cells.”
He added: “The move will also serve to further build our position as a leading Contract Development and Manufacturing Organisation that provides a full range of high quality services.”
About Recipharm
Recipharm is one of Europe’s leading pharmaceutical Contract Development and Manufacturing Organisations (CDMO). Recipharm supplies several hundred different products in a variety of dosage forms including solid dose, semi solids, steriles (liquids and freeze dried), beta-lactams, hormones, dry powder inhalers and granulates, from various facilities across Europe.
Recipharm’s Pharmaceutical Development Services group activities a range from straight forward clinical supply through to more complex product development and formulation. From the pharmaceutical development centre Recipharm can work on a variety of technologies (including sterile products). Formulation Development, Clinical Supplies, Analytical Development, Stability Studies, Packaging Development and Raw Material Selection are all core activities.
RecipharmCobra Biologics has a proven track record in the development and manufacture of recombinant therapeutic proteins, viruses and DNA as well as cell based vaccines and therapies for clinical trials and regulatory approvals. RecipharmCobra Biologics has two GMP approved production facilities, from which a comprehensive service is provided; including cell line development, process and analytical development, GMP manufacture, coordination of formulation and fill/finish activities, and release to clinic.
Website: www.recipharm.com.
